Chrousos George P, Zoumakis Emmanouil
First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, Aghia Sophia Children's Hospital, Athens. Greece.
Curr Mol Pharmacol. 2017;10(4):259-263. doi: 10.2174/1874467210666170109165219.
The Corticotropin-releasing Hormone (CRH) mammalian family members include CRH, urocortin I, Stresscopin (SCP) and Stresscopin-related peptide (SRP), along with the CRH receptors type 1 (CRHR1) and type 2 (CRHR2), and CRH-binding protein (CRH-BP). These family members differ in their tissue distribution and pharmacology. Several studies have provided evidence supporting an important role of this family in the regulation of the neuroendocrine and behavioral responses to stress. Regulation of the relative contribution of CRH and its homologs and the two CRH receptors in brain CRH pathways may be essential in coordinating physiologic responses to stress. The development of disorders related to heightened stress sensitivity and dysregulation of stress-coping mechanisms appears to involve regulatory mechanisms of the CRH family members. Therapeutic agents that target CRH family members may offer a new approach to the treatment of these disorders. The purpose of this review is to summarize the most significant discoveries related to CRH over time.
促肾上腺皮质激素释放激素(CRH)哺乳动物家族成员包括CRH、尿皮质素I、应激肽(SCP)和应激肽相关肽(SRP),以及1型CRH受体(CRHR1)和2型CRH受体(CRHR2),还有CRH结合蛋白(CRH-BP)。这些家族成员在组织分布和药理学方面存在差异。多项研究提供了证据,支持该家族在调节对应激的神经内分泌和行为反应中起重要作用。调节CRH及其同源物以及两种CRH受体在脑CRH通路中的相对贡献,可能对于协调对应激的生理反应至关重要。与应激敏感性增强和应激应对机制失调相关的疾病的发生,似乎涉及CRH家族成员的调节机制。靶向CRH家族成员的治疗药物可能为治疗这些疾病提供一种新方法。本综述的目的是总结随着时间推移与CRH相关的最重要发现。